Nadia Harbeck, MD, PhD, discusses how the monarchE trial, which evaluated the efficacy of endocrine therapy with or without abemaciclib, will change breast cancer treatment.
Nadia Harbeck, MD, PhD, the head of the Breast Center at the European Society of Medial Oncology and the chair of the Conservative Oncology Department at the University of Munich, discusses how the monarchE trial, which evaluated the efficacy of endocrine therapy with or without abemaciclib (Verzenio), will change breast cancer treatment.
According to Harbeck, the monarchE trial is the first study to look at centralized prospective Ki-67 measures with a cut off at 20%. The study accomplished 2 things. First, it validated Ki-67 as a prognostic biomarker, even in clinically high-risk patients. Secondly, it showed the benefit of abemaciclib versus endocrine therapy alone in both Ki-67-high and Ki-67-low tumors, showing that the benefit of the agent was independent of levels.
Additionally, monarchE found that in clinically high-risk Ki-67-low tumors, better outcomes were seen in both arms. According to Harbeck, the findings warrants further follow-up investigation.
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22nd 2024During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Read More